Episode summary
GLP-1s, Peptides, and The Trillion-Dollar Health Revolution
Invest Like the Best
· · 1 hr 38 min · Hosts: Patrick O'Shaughnessy · Guests: Alex Karnal
Summary
Alex Karnal argues that 2025 marked the most exciting year of his biotech investing career because GLP-1 medicines have become the first major commercial proof that medicine is shifting from reactive treatment toward proactive prevention. He says these drugs can lower diabetes risk, heart attack and stroke risk, kidney risk, inflammation, and even addiction risk, and he believes the class can become a more than $100 billion market while signaling a much larger public-health reset.
He frames the “health stack” as a set of offensive and defensive habits and therapies, with five core defensive layers: lipid optimization, cardio-metabolic health, neurocognitive health, inflammatory health, and blood pressure. In his view, existing medicines already cover most of the biology needed to extend healthy life, but adoption is held back by complexity, cost, and convenience rather than a lack of invention. He repeatedly argues that the system needs to move from treating disease late to intervening early and continuously.
Karnal also makes the case that GLP-1s are evolving fast: oral versions, lower monthly prices, and direct-to-consumer channels are accelerating uptake. He contrasts them with PCSK9 inhibitors, which he calls closer to a true “free lunch” because they can sharply reduce LDL cholesterol and cardiovascular risk with little obvious downside. The first half of the conversation sets up a broader thesis that better screening, better delivery, and better drugs could materially reduce long-term healthcare spending and extend lifespan.
Key takeaways
- Karnal says GLP-1s are the first commercial proof of a potential “once-in-a-lifetime trillion dollar revolution in all of public health.”
- He argues the biggest barrier to better health is not invention but access: complexity, cost, and convenience keep people from using medicines that already exist.
- He believes oral GLP-1s at about $150 a month have accelerated adoption because patients want tolerable, lower-friction options they can stay on.
- He says PCSK9 inhibitors can lower LDL by 50% and reduce future heart attack or stroke risk by over 20% in secondary prevention, making them unusually attractive.
- He thinks the best health stack will combine proactive monitoring, better chronic medicines, and AI-assisted follow-through to add roughly a decade of expected lifespan.
Notable quotes
“I would say that 2025 was probably the single most exciting year in my entire journey”
“this as a class of medicines will easily be in excess of a hundred billion dollars a year in revenue”
“what I'm excited about about the GOP1 opportunity is we're seeing the first commercial proof that we're ready to head in that direction”
“each of them has medicines available to help us control our fate”
“I think we've got the combination of of animal model evidence that suggests we really can't get LDL to zero combined with the fact that we've got genetically advantaged people walking around”
How the episode opens
My guest today is Alex Carnell. Alex is probably the most talented bio and healthcare investor that I've ever met. And as you'll see, he is an encyclopedia of all things going on in life sciences.
Alex has been teaching me this topic for more than 5 years. And every single one of our conversations is about as deep as this one that you'll hear today. We cover every single aspect of what makes today's life sciences world so interesting.
Starting with this concept of the health stack, the things that we can do both offensive and defensive to extend our life based on the evidence that he sees in the most exciting companies of today. We talk about cardiovascular disease, neurodeenerative disorders, metabolic disorders, cancers and beyond. And finally, we finish with his remarkable personal story.
I hope you enjoyed this great conversation. You and I have had these conversations now for many, many years. Uh we've been partners and friends for a long time.
And so it's hard to know where to begin the conversation because I suspect we'll go for hours talking about drugs and bio and healthcare and outcomes and a million things that affect us all. You you have this cockpit like view into like what's going on in the state of medicine today. How would you describe the state of the union?
the daily cockpit view that you get of the whole industry like give us a dispatch from that room like what what do you see today?
When I look at this moment in terms of where we are in medicine and I look back over my my 20 years of building and backing biotech companies, I would say that 2025 was probably the single most exciting year in my entire journey.
From the episode’s captions: roughly the first two minutes, lightly cleaned. Keep watching on YouTube →
Topics
- glp-1s
- preventive medicine
- ai drug discovery
- health stack
- peptides
Companies and tickers mentioned
- Braidwell
Watch the episode
Watch “GLP-1s, Peptides, and The Trillion-Dollar Health Revolution” on YouTube
Summary, takeaways and quote selection by Octagon. Quotes are short excerpts; the full conversation is in the episode.
More from Invest Like the Best
Invest Like the Best, this episode and its artwork belong to Colossus | Investing & Business Podcasts. Octagon is not affiliated with the show; this page is an independent summary.
